1. Home
  2. RVMDW vs MSFT Comparison

RVMDW vs MSFT Comparison

Compare RVMDW & MSFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVMDW
  • MSFT
  • Stock Information
  • Founded
  • RVMDW N/A
  • MSFT 1975
  • Country
  • RVMDW United States
  • MSFT United States
  • Employees
  • RVMDW 490
  • MSFT N/A
  • Industry
  • RVMDW
  • MSFT Computer Software: Prepackaged Software
  • Sector
  • RVMDW
  • MSFT Technology
  • Exchange
  • RVMDW Nasdaq
  • MSFT Nasdaq
  • Market Cap
  • RVMDW N/A
  • MSFT N/A
  • IPO Year
  • RVMDW N/A
  • MSFT 1986
  • Fundamental
  • Price
  • RVMDW $0.20
  • MSFT $443.63
  • Analyst Decision
  • RVMDW
  • MSFT Strong Buy
  • Analyst Count
  • RVMDW 0
  • MSFT 30
  • Target Price
  • RVMDW N/A
  • MSFT $512.07
  • AVG Volume (30 Days)
  • RVMDW N/A
  • MSFT 19.4M
  • Earning Date
  • RVMDW N/A
  • MSFT 01-29-2025
  • Dividend Yield
  • RVMDW N/A
  • MSFT 0.74%
  • EPS Growth
  • RVMDW N/A
  • MSFT 17.35
  • EPS
  • RVMDW N/A
  • MSFT 12.11
  • Revenue
  • RVMDW N/A
  • MSFT $254,190,000,000.00
  • Revenue This Year
  • RVMDW N/A
  • MSFT $15.84
  • Revenue Next Year
  • RVMDW N/A
  • MSFT $14.24
  • P/E Ratio
  • RVMDW N/A
  • MSFT $36.85
  • Revenue Growth
  • RVMDW N/A
  • MSFT 16.44
  • 52 Week Low
  • RVMDW N/A
  • MSFT $385.58
  • 52 Week High
  • RVMDW N/A
  • MSFT $468.35
  • Technical
  • Relative Strength Index (RSI)
  • RVMDW N/A
  • MSFT 60.45
  • Support Level
  • RVMDW N/A
  • MSFT $425.60
  • Resistance Level
  • RVMDW N/A
  • MSFT $447.27
  • Average True Range (ATR)
  • RVMDW 0.00
  • MSFT 7.54
  • MACD
  • RVMDW 0.00
  • MSFT 2.26
  • Stochastic Oscillator
  • RVMDW 0.00
  • MSFT 88.05

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: